High-throughput technologies do not only provide novel means for basic biological research but also for clinical applications in hospitals. For instance, the usage of gene expression profiles as prognostic biomarkers for predicting, e.g., cancer progression, has found widespread interest. Aside from predicting the progression of patients it is generally believed that such prognostic biomarkers provide also valuable information about disease mechanisms and the underlying molecular processes that are causal for a disorder. However, the latter assumption has been challenged. In this paper, we study this problem for prostate cancer. Specifically, we investigate a large number of previously published prognostic signatures of prostate cancer base...
Background Optimum management of clinically localised prostate cancer presents unique challenges bec...
We show here that gene expression profiling, performed with conventional techniques and focused on a...
There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological d...
High-throughput technologies do not only provide novel means for basic biological research but also ...
High-throughput technologies do not only provide novel means for basic biological research but also ...
Prognostic biomarkers can have an important role in the clinical practice because they allow stratif...
Prognostic biomarkers can have an important role in the clinical practice because they allow stratif...
Prognostic biomarkers can have an important role in the clinical practice because they allow stratif...
The advent of high-throughput sequencing and microarray technologies has improved our overall unders...
The identification of prognostic biomarkers for predicting cancer progression is an important proble...
SummaryBackgroundOptimum management of clinically localised prostate cancer presents unique challeng...
Background: Current prostate cancer prognostic models are based on pre-treatment prostate specific a...
Background: Treatment planning of localised prostate cancer remains challenging. Besides conventiona...
Introduction. Predicting the aggressiveness of prostate cancer at biopsy is invaluable in making tre...
BACKGROUND: Optimum management of clinically localised prostate cancer presents unique challenges be...
Background Optimum management of clinically localised prostate cancer presents unique challenges bec...
We show here that gene expression profiling, performed with conventional techniques and focused on a...
There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological d...
High-throughput technologies do not only provide novel means for basic biological research but also ...
High-throughput technologies do not only provide novel means for basic biological research but also ...
Prognostic biomarkers can have an important role in the clinical practice because they allow stratif...
Prognostic biomarkers can have an important role in the clinical practice because they allow stratif...
Prognostic biomarkers can have an important role in the clinical practice because they allow stratif...
The advent of high-throughput sequencing and microarray technologies has improved our overall unders...
The identification of prognostic biomarkers for predicting cancer progression is an important proble...
SummaryBackgroundOptimum management of clinically localised prostate cancer presents unique challeng...
Background: Current prostate cancer prognostic models are based on pre-treatment prostate specific a...
Background: Treatment planning of localised prostate cancer remains challenging. Besides conventiona...
Introduction. Predicting the aggressiveness of prostate cancer at biopsy is invaluable in making tre...
BACKGROUND: Optimum management of clinically localised prostate cancer presents unique challenges be...
Background Optimum management of clinically localised prostate cancer presents unique challenges bec...
We show here that gene expression profiling, performed with conventional techniques and focused on a...
There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological d...